Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 8, 2003, Pages 1345-1351

  Grosser, Nina ^b   Schröder, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NONE

Author keywords

Antioxidant defense mechanism; Aspirin; Cyclic GMP; Endothelium; Nitric oxide

Indexed keywords

ACETYLSALICYLIC ACID; ARGININE; CITRULLINE; CYCLIC GMP; GUANYLATE CYCLASE INHIBITOR; HYDROGEN PEROXIDE; IMIDAZOLINE DERIVATIVE; INDOMETACIN; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOXALINE DERIVATIVE; SALICYLIC ACID; SCAVENGER;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ASPIRIN; CATTLE; CELL SURVIVAL; CELLS, CULTURED; CITRULLINE; CYCLIC GMP; CYCLIC N-OXIDES; CYTOPROTECTION; DICLOFENAC; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GUANYLATE CYCLASE; HYDROGEN PEROXIDE; IMIDAZOLES; INDOMETHACIN; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OMEGA-N-METHYLARGININE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SWINE;

EID: 0041732163     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000083296.57581.AE     Document Type: Article

References (54)

1. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease: Special Writing Group. Circulation. 1993;87:659-675.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
3. Samuelsson B, Granstrom E, Green K, Hamberg M, Hammarstrom S. Prostaglandins. Annu Rev Biochem. 1975;44:669-695.
4. Reilly IA, FitzGerald GA. Aspirin in cardiovascular disease. Drugs. 1988;35:154-176.
5. Aruoma OI, Halliwell B. The iron-binding, and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica. 1988;18:459-470.
6. Woollard AC, Wolff SP, Bascal ZA. Antioxidant characteristics of some potential anticataract agents: studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radic Biol Med. 1990;9:299-305.
7. Podhaisky HP, Abate A, Polte T, Oberle S, Schröder H. Aspirin protects endothelial cells from oxidative stress: possible synergism with vitamin E. FEBS Lett. 1997;417:349-351.
8. Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart. 1997;77:333-337.
9. Wu R, Lamontagne D, de Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 2002;105:387-392.
10. Wink DA, Hanbauer I, Krishna MC, DeGraff, W, Gamson J, Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA. 1993;90:9813-9817.
11. Chang J, Rao NV, Markewitz BA, Hoidal JR, Michael JR. Nitric oxide donor prevents hydrogen peroxide-mediated endothelial cell injury. Am J Physiol. 1996;270:L931-L940.
12. Polte T, Oberle S, Schröder H. Nitric oxide protects endothelial cells from tumor necrosis factor-α-mediated cytotoxicity: possible involvement of cyclic GMP. FEBS Lett. 1997;409:46-48.
13. Oberle S, Schröder H. Ferritin may mediate SIN-1-induced protection against oxidative stress. Nitric Oxide 1997;1:308-314.
14. Fernandez-Tome P, Lizasoain I, Leza JC, Lorenzo P, Moro MA. Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones. Neuropharmacology. 1999;38:1307-1315.
15. Motterlini R, Foresti R, Intaglietta M, Winslow RM. NO-mediated activation of heme oxygenase: endogenous cytoprotection against oxidative stress to endothelium. Am J Physiol. 1996;270:H107-H114.
16. Oberle S, Polte T, Abate A, Podhaisky HP, Schröder H. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res. 1998;82:1016-1020.
17. Polte T, Abate A, Dennery PA, Schröder H. Heme oxygenase-1 is a cGMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide. Arterioscler Thromb Vasc Biol. 2000;20:1209-1215.
18. Schröder H, Strobach H, Schrör K. Nitric oxide but not prostacyclin is an autocrine endothelial mediator. Biochem Pharmacol. 1992;43:533-537.
19. Li H, Förstermann U. Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitric-oxide synthase gene. Mol Pharmacol. 2000:57:427-435.
20. Schröder H, Leitman DC, Bennett BM, Waldman SA, Murad F. Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther. 1988;245:413-418.
21. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984;68:167-175.
22. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115:61-69.
23. Nakamura M, Nakamura S. One- and two-electron oxidations of luminol by peroxidase systems. Free Radic Biol Med. 1998;24:537-544.
24. Pizzinat N, Copin N, Vindis C, Parini A, Cambon C. Reactive oxygen species production by monoamine oxidases in intact cells. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:428-431.
25. Grosser N, Schröder H. A common pathway for nitric oxide release from NO-aspirin and glyceryl trinitrate. Biochem Biophys Res Commun. 2000;274:255-258.
26. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A. 1990;87:682-685.
27. Heller R, Münscher-Paulig F, Grabner R, Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem. 1999;274:8254-8260.
28. Akarasereenont P, Mitchell JA, Appleton I, Thiemermann C, Vane JR. Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol. 1994;113:1522-1528.
29. Monobe H, Yamanari H, Nakamura K, Ohe T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol. 2001;24:705-709.
30. Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation. 1993;87:1873-1879.
31. Kodama M, Yamasaki Y, Sakamoto K, Yoshioka R, Matsuhisa M, Kajimoto Y, Kosugi K, Ueda N, Hori M. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res. 2000;97:239-245.
32. Cyrus T, Sung S, Zhao L, Funk CD, Tang S, Prafico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2002;106:1282-1287.
33. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97:716-720.
34. Drexler H. Nitric oxide and coronary endothelial dysfunction in humans. Cardiovasc Res. 1999;43:572-579.
35. Bell DM. Markers for progression of coronary disease. Pharmacotherapy. 2001;21:190S-194S.
36. Spieker LE, Lüscher TF, Noll G. Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis. J Cardiovasc Pharmacol. 2001;38(suppl 2):S35-S41.
37. Akaike T, Maeda H. Quantitation of nitric oxide using 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO). Methods Enzymol. 1996;268:211-221.
38. Kuhn M, Otten A, Frölich JC, Förstermann U. Glyceryl trinitrate increases platelet cyclic GMP after metabolism in fibroblasts. Eur J Pharmacol. 1991;200:175-178.
39. Mülsch A, Bauersachs J, Schäfer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol. 1997;120:681-689.
40. Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol. 1998;53:123-127.
41. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzbom E, Pleiss U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215.
42. Schmidt K, Schrammel A, Koesling D, Mayer B. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. Mol Pharmacol. 2001;59:220-224.
43. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A. 1996;93:1480-1485.
44. Polte T, Schröder H. Cyclic AMP mediates endothelial protection by nitric oxide. Biochem Biophys Res Commun. 1998;251:460-465.
45. Recalcati S, Taramelli D, Conte D, Cairo G. Nitric oxide-mediated induction of ferritin synthesis in J774 macrophages by inflammatory cytokines: role of selective iron regulatory protein-2 downregulation. Blood. 1998;91:1059-1066.
46. Abate A, Vreman HJ, Dennery PA, Schröder H. Aspirin induces heme oxygenase-1 protein synthesis and activity in endothelial cells. Circulation. 2001;104(suppl 2):1152. Abstract.
47. Schröder H, Leitman D, Hayward L, Bennett B, Murad F. Cultured rat lung fibroblasts as a model for organic nitrate-induced cyclic GMP accumulation and activation of guanylate cyclase. J Appl Cardiol. 1987;2:301-311.
48. Ishii K, Sheng H, Warner TD, Förstermann U, Murad F. A simple and sensitive bioassay method for detection of EDRF with RFL-6 rat lung fibroblasts. Am J Physiol. 1991;261:H598-H603.
49. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1-R12.
50. Lopez-Farre A, Caramelo C, Esteban A, Alberola ML, Millas I, Monton M, Casado S. Effects of aspirin on platelet-neutrophil interactions: role of nitric oxide and endothelin-1. Circulation. 1995;91:2080-2088.
51. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057-2072.
52. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 1994;265:956-959.
53. Proudfoot AT. Toxicity of salicylates. Am J Med. 1983;75:99-103.
54. Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol. 1999;84:404-409.